Remote Ischemic Conditioning (RIC)

Has been shown to significantly reduce Ischemia Reperfusion Injury (IRI) caused by cardiac events or cardiac intervention

Learn more about RIC
The autoRIC® Device

Automates RIC provides
Safe, Convenient and Accurate therapy delivery

Approved for use in Canada and EU

CAUTION: Investigational Device. Limited by United States law to Investigational Use.

Discover the autoRIC® Device
RIC Clinical Research Trials

Over 100 completed and ongoing trials with more than 20,000 patients world-wide, zero adverse events reported

View RIC Clinical Trials
RIC Markets

$2 Billion Acute Market: Hospital and pre-hospital settings
$4-6 Billion Chronic Market: Heart Failure, Stroke, Home & Public settings

Explore RIC Markets

CellAegis Devices Inc. - Media Coverage

March 14, 2017 - CellAegis Devices Announces US$9.5 Million Financing to Support Clinical and Regulatory Advancement of its autoRIC® Device

CellAegis Devices Announces US$ 9.5 million Series C financing to support a U.S. clinical trial and de novo 510(k) regulatory filing for marketing of its autoRIC® Device as an adjunct therapy to stenting. This device automatically delivers Remote Ischemic Conditioning (RIC) to provide a noninvasive, cardio-protective therapy shown to reduce heart damage during heart attacks and other cardiovascular procedures.

July 25, 2016 - Peel-Halton Region Aims to Minimize Damage to Heart Attack Patients

Led by William Osler Health System (Osler), the study brings together teams from across the health care industry, including Peel Regional Paramedic Services, Halton Regional Paramedic Services, Trillium Health Partners, and the Sunnybrook Centre for Prehospital Medicine, with support from Rescu and the Li Ka Shing Knowledge Institute at St. Michael’s Hospital.

July 6, 2015 - RSK Medical and CellAegis Devices partner in the Canadian Health Care Market

RSK Medical and CellAegis Devices partner in the Canadian Health Care Market to improve outcomes for heart attack patients. RSK Medical will distribute CellAegis’ innovative Canadian Medical Technology to reduce Heart Damage.

CellAegis Devices: 2012 Mind to Market Award Finalist

CellAegis autoRIC® Device
European Hospital Early Adopter Program

Safe for your patient, Simple for you!
Preferred Consumables Pricing
Capital Costs Eliminated
Three-year warranty on Device(s)

Better Cath Lab Outcomes, Improved Clinical Benefit
pPCI: Infarct size reduction, MACE & mortality reduced
ePCI: Troponin and MACCE reductions
Coronary Angiogram/TAVR: Significant reduction in CI-AKI

For more information about the autoRIC® Device or to inquire about our European Hospital Early Adopter Program:

Call us: 1-647-722-9601 Email us: